Annis Gardner Whiting Capital Advisors’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Annis Gardner Whiting Capital Advisors’s Portfolio EPRX Stock Details EPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$397K	Buy	+60,000	New	+$414K	0.06%	236

Other funds holding EPRX

Beutel, Goodman & Co Toronto, Ontario, Canada $13.6B AUM 17.82% 1-Year Est. Return

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Balyasny Asset Management

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Scotia Capital Toronto, Ontario, Canada $26.8B AUM 33.07% 1-Year Est. Return

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Annis Gardner Whiting Capital Advisors's EPRX Position: Q2 2026 in Review

Annis Gardner Whiting Capital Advisors opened a new position in Eupraxia Pharmaceuticals (EPRX) in Q2 2026: 60,000 shares worth $397K. The stake represents 0.06% of the portfolio and ranks #236 among its holdings.

68 funds tracked by Wall St. Rank hold EPRX as of Q2 2026.

Annis Gardner Whiting Capital Advisors held 60,000 shares of Eupraxia Pharmaceuticals worth $397K as of Q2 2026.
Eupraxia Pharmaceuticals was a new Annis Gardner Whiting Capital Advisors position in Q2 2026.
Eupraxia Pharmaceuticals made up 0.06% of Annis Gardner Whiting Capital Advisors's portfolio in Q2 2026, its #236 holding.
68 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q2 2026.

Based on Annis Gardner Whiting Capital Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.